View Older Stories View More Recent Stories

May 20, 2025 04:20PM Soleno Therapeutics (SLNO) Announces Data Presentation Showing that Resumption of Treatment with VYKAT
May 20, 2025 08:30AM Piper Sandler: 'We Remain Bullish and View Soleno Therapeutics (SLNO) As a Key Name to Own'
May 8, 2025 06:12AM Oppenheimer Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
May 7, 2025 04:22PM Soleno Therapeutics, Inc. (SLNO) Misses Q1 EPS by 6c
May 7, 2025 04:02PM Soleno Therapeutics (SLNO) Provides Update on U.S. Launch of VYKAT XR
Apr 24, 2025 08:22AM Soleno Therapeutics Inc. (SLNO) PT Raised to $145 at Piper Sandler
Apr 14, 2025 07:02AM Soleno Therapeutics (SLNO) Announces VYKAT XR Launch
Apr 11, 2025 09:44AM Piper Sandler: 'What Biotech Names to Own in Market Volatility'
Apr 2, 2025 07:04AM Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
Apr 1, 2025 07:11AM Piper Sandler 'Remains Bullish' on Soleno Therapeutics Inc. (SLNO) Following VYKAT XR Approval
Mar 31, 2025 06:40AM Soleno Therapeutics Inc. (SLNO) PT Raised to $100 at H.C. Wainwright
Mar 28, 2025 07:26AM Soleno Therapeutics Inc. (SLNO) PT Raised to $108 at Stifel
Mar 28, 2025 06:59AM Soleno Therapeutics Inc. (SLNO) PT Raised to $81 at Guggenheim
Mar 27, 2025 08:17AM Piper Sandler on Soleno Therapeutics Inc. (SLNO): 'VYKAT XR Approved With Spot Clean Label & Lucrative Pricing'
Mar 27, 2025 07:53AM Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)
Mar 27, 2025 07:40AM Soleno Therapeutics Inc. (SLNO) PT Raised to $105 at Oppenheimer
Mar 27, 2025 07:37AM Soleno Therapeutics Inc. (SLNO) PT Raised to $123 at Cantor Fitzgerald
Mar 27, 2025 05:12AM Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)
Mar 27, 2025 04:59AM Soleno Therapeutics Inc. (SLNO) PT Raised to $102 at Baird
Mar 26, 2025 05:17PM Soleno Therapeutics (SLNO) announced FDA approval for Prader-Willi Syndrome treatment
Mar 26, 2025 04:04PM Soleno Therapeutics (SLNO) Halted, News Pending
Mar 26, 2025 04:52AM Increasing unusual call option volume: SLNO ATEC COPX CRMD PRCH EU BJ SMG BTU
Mar 12, 2025 09:07AM Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)
Mar 5, 2025 06:45AM Stifel Resumes Soleno Therapeutics Inc. (SLNO) at Buy
Mar 3, 2025 08:49AM Cantor Fitzgerald Reiterates Overweight Rating on Soleno Therapeutics Inc. (SLNO)
Dec 19, 2024 09:42AM Stifel Names Top Picks in Biotechnology 2025 Outlook Note
Dec 17, 2024 04:06PM Soleno Therapeutics (SLNO) Enters Into $200M Debt Financing with Oxford Finance LLC
Dec 2, 2024 06:58AM Baird Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
Dec 2, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)
Nov 29, 2024 11:46AM Baird Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
Nov 26, 2024 08:31AM Soleno Therapeutics (SLNO) Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
Nov 6, 2024 04:26PM Soleno Therapeutics, Inc. (SLNO) Misses Q3 EPS by 122c
Oct 28, 2024 06:42AM Soleno Therapeutics Inc. (SLNO) PT Raised to $73 at Oppenheimer
Oct 8, 2024 02:57PM Laidlaw Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)
Oct 8, 2024 10:00AM Baird Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
Oct 8, 2024 09:17AM Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)
Oct 8, 2024 09:14AM Oppenheimer Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
Oct 8, 2024 08:31AM Soleno Therapeutics (SLNO) Announces Regulatory Update on DCCR Extended-Release Tablets to Treat Prader-Willi Syndrome
Sep 30, 2024 04:43PM Soleno Therapeutics Inc. (SLNO) PT Raised to $74 at Stifel
Sep 27, 2024 08:38AM Piper Sandler Reiterates Overweight Rating on Soleno Therapeutics Inc. (SLNO)
Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025
Sep 3, 2024 06:32AM H.C. Wainwright Starts Soleno Therapeutics Inc. (SLNO) at Buy
Aug 27, 2024 11:42AM Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)
Aug 27, 2024 11:37AM Oppenheimer Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
Aug 27, 2024 08:08AM Soleno Therapeutics (SLNO) Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
Aug 22, 2024 06:58AM Piper Sandler Reiterates Overweight Rating on Soleno Therapeutics Inc. (SLNO)
Aug 15, 2024 08:01AM Soleno Therapeutics (SLNO) Announces Board Changes
Aug 7, 2024 04:42PM Soleno Therapeutics, Inc. (SLNO) Tops Q2 EPS by 2c
Jun 28, 2024 08:01AM Soleno Therapeutics (SLNO) Announces Submission of NDA to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
View More Recent Stories View Older Stories